- Home
- PMAX vs RNAZ Comparison
PMAX vs RNAZ Comparison
Compare PMAX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- RNAZ
- Stock Information
- Founded
- PMAX 2019
- RNAZ 2016
- Country
- PMAX Hong Kong
- RNAZ United States
- Employees
- PMAX N/A
- RNAZ N/A
- Industry
- PMAX
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- RNAZ Health Care
- Exchange
- PMAX Nasdaq
- RNAZ Nasdaq
- Market Cap
- PMAX 6.5M
- RNAZ 6.1M
- IPO Year
- PMAX 2024
- RNAZ 2021
- Fundamental
- Price
- PMAX $0.38
- RNAZ $7.97
- Analyst Decision
- PMAX
- RNAZ Strong Buy
- Analyst Count
- PMAX 0
- RNAZ 1
- Target Price
- PMAX N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- PMAX 730.6K
- RNAZ 32.8K
- Earning Date
- PMAX 04-28-2025
- RNAZ 08-13-2025
- Dividend Yield
- PMAX N/A
- RNAZ N/A
- EPS Growth
- PMAX N/A
- RNAZ N/A
- EPS
- PMAX N/A
- RNAZ N/A
- Revenue
- PMAX $4,694,079.00
- RNAZ N/A
- Revenue This Year
- PMAX N/A
- RNAZ N/A
- Revenue Next Year
- PMAX N/A
- RNAZ N/A
- P/E Ratio
- PMAX N/A
- RNAZ N/A
- Revenue Growth
- PMAX N/A
- RNAZ N/A
- 52 Week Low
- PMAX $0.28
- RNAZ $6.15
- 52 Week High
- PMAX $4.70
- RNAZ $970.20
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- RNAZ 47.04
- Support Level
- PMAX N/A
- RNAZ $7.32
- Resistance Level
- PMAX N/A
- RNAZ $8.48
- Average True Range (ATR)
- PMAX 0.00
- RNAZ 0.58
- MACD
- PMAX 0.00
- RNAZ 0.41
- Stochastic Oscillator
- PMAX 0.00
- RNAZ 70.77
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.